

# **Product** Data Sheet

## **Omesdafexor**

Cat. No.: HY-147296

CAS No.: 2244440-85-3

Molecular Formula:  $C_{34}H_{43}N_3O_3$ Molecular Weight: 541.72

Target: FXR

Pathway: Metabolic Enzyme/Protease

Storage: Powder -20°C 3 years 4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (184.60 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.8460 mL	9.2299 mL	18.4597 mL
	5 mM	0.3692 mL	1.8460 mL	3.6919 mL
	10 mM	0.1846 mL	0.9230 mL	1.8460 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (4.61 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility: 2.5 mg/mL (4.61 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (4.61 mM); Clear solution; Need ultrasonic

### **BIOLOGICAL ACTIVITY**

Description

Omesdafexor is a FXR agonist. Omesdafexor can be used in the research of liver disease or a metabolic inflammation-mediated disease [1][2].

#### **REFERENCES**

 $[1]. \ https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf?sfvrsn=8544ca1e\_3\&download=true$ 

2]. Song, Kenneth, et al. Farnesoid X receptor agonists for the treatment of a liver disease or a metabolic inflammation-mediated disease or disorder. Patent VO2020061114.						
			edical applications. For research use			
	Tel: 609-228-6898	Fax: 609-228-5909 Deer Park Dr, Suite Q, Monmo	E-mail: tech@MedChemExpress.	com		
	Addiess. 1	. Deer Fark Dr., Suite Q, Monnik	outil sufficient, NS 00032, OSA			

Page 2 of 2 www.MedChemExpress.com